JANX FY2025 SEC EDGAR DEF 14A #103 of 168 in industry

Janux Therapeutics, Inc. CEO pay ratio

The CEO earned $13.5M in FY2025 against median worker pay of $450,208 · Chemicals & Pharmaceuticals.

Chemicals & Pharmaceuticals peers All rankings
State
DE
Filing date
2026-04-28
Industry
Chemicals & Pharmaceuticals
Industry rank
#103/168

Data updated August 2026

Subscribe to Janux Therapeutics, Inc. CEO pay filing updates (RSS)

CEO-to-worker pay ratio
30:1
Below Average (Scale: 0–1000:1)
CEO pay
$13.5M
Median worker
$450,208

Answer first

Janux Therapeutics, Inc.'s FY2025 CEO total of $13.5M ranks #359 of 1,423 complete filings; its 30:1 pay ratio ranks #1140. Dollar rank is not ratio rank.

According to the same FY2025 complete-filing cohort used on the rankings boards (CEO total, median worker, and ratio all present). Median worker pay is $450,208. Industry placement uses the FY2025 SIC-28 peer cohort (# 103 of 168, 39th percentile - below the industry median pay ratio). Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.

Dollar rank
#359
$13.5M of 1,423 FY2025
Ratio rank
#1140
30:1 of 1,423
Industry pct
39th
below the industry median pay ratio

How Janux Therapeutics, Inc. ranks nationally

Janux Therapeutics, Inc. CEO pay vs. every FY2025 complete filing

Total CEO compensation, the full national distribution, this company marked

$13,506,231 Top 25% higher than 75% of 1,423 companies

$0–$2,500,000: 304 companies (21%). Below this entry. $2,500,000–$5,000,000: 182 companies (13%). Below this entry. $5,000,000–$7,500,000: 208 companies (15%). Below this entry. $7,500,000–$10,000,000: 192 companies (13%). Below this entry. $10,000,000–$12,500,000: 139 companies (10%). Below this entry. $12,500,000–$15,000,000: 91 companies (6%). This entry sits in this band. $15,000,000–$17,500,000: 88 companies (6%). Above this entry. $17,500,000–$20,000,000: 54 companies (4%). Above this entry. $20,000,000–$22,500,000: 24 companies (2%). Above this entry. $22,500,000–$25,000,000: 34 companies (2%). Above this entry. $25,000,000–$27,500,000: 24 companies (2%). Above this entry. $27,500,000–$30,000,000: 16 companies (1%). Above this entry. $30,000,000–$32,500,000: 10 companies (1%). Above this entry. $32,500,000–$35,000,000: 7 companies (0%). Above this entry. $35,000,000–$37,500,000: 9 companies (1%). Above this entry. $37,500,000–$40,000,000: 6 companies (0%). Above this entry. $40,000,000–$42,500,000: 1 companies (0%). Above this entry. $42,500,000–$45,000,000: 1 companies (0%). Above this entry. $45,000,000–$47,500,000: 6 companies (0%). Above this entry. $47,500,000–$50,000,000: 27 companies (2%). Above this entry. This company $0 $50M+ every complete-filing company, bucketed by value

Each bar is a $2500K-wide band; taller bars hold more companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source SEC DEF 14A Section 953(b) disclosures, PlainCEOPay extract · FY2025

Janux Therapeutics, Inc. vs. Chemicals & Pharmaceuticals peers

CEO total pay ($13.5M) against pay ratio (30:1) for Janux Therapeutics, Inc. (marked) and its 5 closest same-industry peers, against the Chemicals & Pharmaceuticals industry median on both axes.

Pay + gap both highContained pay, wide gapHigh pay, contained gapBelow peer norms on both3149280.95861815.4857435011286884.513999419.128.4:131.9:135.5:139.1:142.6:1CEO total payPay ratio (CEO : median worker)Janux Therapeutics, Inc., CEO total pay: 13506231 · Pay ratio (CEO : median worker): 30:1Janux Therapeutics, Inc.Protagonist Therapeutics, Inc, CEO total pay: 12852660 · Pay ratio (CEO : median worker): 30:1Protagonist Therapeutics, IncAlkermes plc., CEO total pay: 8002710 · Pay ratio (CEO : median worker): 30:1Alkermes plc.Green Plains Inc., CEO total pay: 3642469 · Pay ratio (CEO : median worker): 31:1Green Plains Inc.Iovance Biotherapeutics, Inc., CEO total pay: 4755679 · Pay ratio (CEO : median worker): 31:1Iovance Biotherapeutics, Inc.Structure Therapeutics Inc., CEO total pay: 8520403 · Pay ratio (CEO : median worker): 29:1Structure Therapeutics Inc.
Janux Therapeutics, Inc. vs. Chemicals & Pharmaceuticals peers, plotted against the industry's $7.9M median CEO total and 42:1 median pay ratio.

Ratio bands among Chemicals & Pharmaceuticals peers

Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.

CEO Compensation Breakdown, FY2025

A component-level pay breakdown is not reported in Janux Therapeutics, Inc.'s structured SEC pay-ratio disclosure. See our methodology →

Industry Comparison - Chemicals & Pharmaceuticals

This Company's Ratio
30:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$13.5M
Companies in Industry
168
vs. Industry Median
Below
#103 of 168 by pay ratio in this industry View all companies in Chemicals & Pharmaceuticals →

Janux Therapeutics, Inc.: MODEST · HEAVY pay ratio

Janux Therapeutics, Inc.'s 30:1 ratio ranks #1140 of 1,423 FY2025 complete filings (lower third by ratio). the CEO earned 30× the median employee ($450,208) in FY2025.

Median employee $450,208 (ELITE-MED); MODEST · HEAVY stamps put about 30 median-wage years per CEO year.

CEO Total Pay

$13.5M

FY2025 Summary Compensation, above median

Pay Ratio

30:1

Below typical

Janux Therapeutics, Inc. in the lower-ratio third

Janux Therapeutics, Inc.'s 30:1 ratio ranks #1140 of 1,423 FY2025 complete filings (lower third by ratio). The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Janux Therapeutics, Inc.'s $13.5M CEO total is above the $7.9M industry median CEO pay.

Dollar rank #359 and ratio rank #1140 split - treat 30:1 as a disclosure, not a fairness score. Open Chemicals & Pharmaceuticals peers.

Key Data, FY2025

Total Compensation
$13.5M
Median Employee Pay
$450,208
Pay Ratio
30:1
Filing Date
2026-04-28

Company Info

Ticker
JANX
CIK
1817713
Industry
Chemicals & Pharmaceuticals
SIC Code
2834
State
DE
View SEC filings →
SEC EDGAR DEF 14A for CIK 1817713, FY2025. Informational only, not investment advice. Verify on EDGAR.

Read our methodology - how this data is sourced, computed, and verified. Janux Therapeutics, Inc.'s 30:1 ratio ranks #1140 of 1,423 FY2025 complete filings (lower third by ratio).

Read with Janux Therapeutics, Inc.

ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps MODEST · HEAVY · ELITE-MED.

Verisk Analytics, Inc. · HEAVY

ABS(ceo_total_comp) peer at $13.5M (Δ $35K heavier vs Janux Therapeutics, Inc.); STEEP · PAR-MED vs this page's MODEST · HEAVY · ELITE-MED.
Neurocrine Biosciences Inc · HEAVY

ABS(ceo_total_comp) peer at $13.4M (Δ $57K lighter vs Janux Therapeutics, Inc.); MODEST · ELITE-MED vs this page's MODEST · HEAVY · ELITE-MED.
Wyndham Hotels & Resorts, Inc. · HEAVY

ABS(ceo_total_comp) peer at $13.6M (Δ $60K heavier vs Janux Therapeutics, Inc.); MID · HIGH-MED vs this page's MODEST · HEAVY · ELITE-MED.
Cricut, Inc. · HEAVY

ABS(ceo_total_comp) peer at $13.4M (Δ $64K lighter vs Janux Therapeutics, Inc.); MID · HIGH-MED vs this page's MODEST · HEAVY · ELITE-MED.
Protagonist Therapeutics, Inc (SIC 28 pole)

Protagonist Therapeutics, Inc stamps MODEST · HEAVY nearest in-SIC by ABS(pay_ratio) to Janux Therapeutics, Inc.'s MODEST filing.
National dual ranks · #359/#1140

Janux Therapeutics, Inc.'s FY2025 package sits #359 by CEO dollars and #1140 by ratio under HEAVY · MODEST.
Ratio primer · MODEST

Janux Therapeutics, Inc.'s MODEST stamp sits in the lower Item 402(u) band - start with how the ratio is disclosed before comparing peers.
Data sourced from SEC EDGAR DEF 14A for Janux Therapeutics, Inc. (CIK 1817713), FY2025. See our methodology. Aggregated by PlainCEOPay as of August 2026.

Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.